PBR111

PreclinicalSmall molecule

UUniversity of North Carolina, Chapel Hill

PBR111 is one of 9 small molecule programs targeting Humans. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HumansCompleted

HumansPreclinical

Completed

Competition

Competitive Landscape

11 competitors in Humans

#DrugCompanyPhaseTrials

Lexapro

AbbVie

Approved

1 2

Reboxetine

UUniversity of Zurich

Preclinical

1 3

Remitch

SShandong New Time Pharmaceutical Co., LTD

Preclinical

1 4

Astaxanthin

SSheba Medical Center

Preclinical

1 5

Salmonella Typhi

UUniversity of Oxford

Preclinical

1 6

Nalfurafine Hydrochloride

SShandong New Time Pharmaceutical Co., LTD

Preclinical

1 7

GLP-2

GGlostrup University Hospital, Copenhagen

Preclinical

1 8

PBR111

UUniversity of North Carolina, Chapel Hill

Preclinical

1 9

Stool Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Humans1 trial

Radiation Dosimetry of the 18 kDa Translocator Protein Ligand [18F]PBR111 in Humans

Completed·PProf. Daniele Zullino·N/A·NCT06398392·6 enrolled

Inflammation1 trial

Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions

Completed·IInstitute for Neurodegenerative Disorders·Phase 1·NCT01209156·11 enrolled

Prospective1 trial

NFL LONG Prospective Study

Enrolling by invitation·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT04263337·250 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for PBR111. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PBR111 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PBR111. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of North Carolina, Chapel Hill company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of North Carolina, Chapel Hill

PBR111

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Humans1 trial

Inflammation1 trial

Prospective1 trial

References

Drug Info

Quick Facts

Related News